Versigent (NYSE:VGNT – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.34, Zacks reports. The firm had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.29 billion.
Here are the key takeaways from Versigent’s conference call:
- Versigent reported strong second-quarter results, with net sales up 11% year over year to $2.4 billion, adjusted EBITDA up 25% to $272 million, and margin expanding 120 basis points to 11.1%. Underlying adjusted sales growth was approximately 5%, outpacing relatively flat-to-down global automotive production.
- The company cited robust commercial momentum, including $2.8 billion in second-quarter bookings and 39 large-scale program launches with more than 99% quality and on-time delivery. Growth was particularly strong in the Americas and Asia-Pacific, supported by customer launches and China-related vehicle exports.
- Versigent raised its 2026 sales guidance to $9.4 billion-$9.6 billion, primarily due to higher copper pass-throughs and favorable foreign exchange, but maintained adjusted EBITDA guidance of $950 million-$1.03 billion because those macro benefits are not expected to materially improve profitability. The company also reaffirmed free cash flow guidance of $200 million-$300 million.
- Management expects second-half pressure from lower global automotive production, customer-specific schedule reductions, softer EMEA demand, and temporary volume and absorption impacts from an unusually high number of program launches. European adjusted sales declined 11% in the quarter, prompting targeted actions to improve regional competitiveness.
- The company initiated a quarterly dividend of $0.13 per share and has $250 million remaining under its share-repurchase authorization, supported by its projected cash generation and approximately $1 billion of cumulative free cash flow from 2026 through 2028. Management also identified commercial vehicles, agriculture, battery energy storage, and robotics as potential longer-term growth opportunities not included meaningfully in its 2028 outlook.
Versigent Price Performance
Shares of NYSE VGNT traded down $1.22 during mid-day trading on Thursday, reaching $43.81. 330,944 shares of the company’s stock were exchanged, compared to its average volume of 2,060,926. Versigent has a 52 week low of $26.34 and a 52 week high of $50.88. The stock has a 50-day moving average price of $43.39.
Versigent Announces Dividend
Analyst Ratings Changes
VGNT has been the subject of several research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and issued a $59.00 price target on shares of Versigent in a report on Wednesday. Zacks Research raised shares of Versigent from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 2nd. Morgan Stanley initiated coverage on shares of Versigent in a research note on Friday, May 8th. They issued an “overweight” rating and a $51.00 price target on the stock. TD Cowen raised their price objective on shares of Versigent from $49.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday. Finally, BNP Paribas Exane started coverage on Versigent in a research report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $53.25.
Read Our Latest Report on VGNT
Featured Articles
- Five stocks we like better than Versigent
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
- Astera Labs’ Post-Earnings Pullback May Be Last Chance to Buy Below $360
- McDonald’s Stock Sell-Off: Justified Warning or Buying Opportunity?
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
